Hydroxychloroquine Associated With Far Lower COVID-19 Mortality: Study The French study included 30,202 patients. | "Just 0.8% of patients at a facility in France who received hydroxychloroquine and an antibiotic died, compared to 4.8% of patients who did not receive the drug combination."

submitted by stickdog from archive.ph

all 5 comments
sorted by:
new (suggested)
topinsightfulfun

[–]hfxB0oyA 2 insightful - 2 fun2 insightful - 1 fun3 insightful - 2 fun -  (0 children)

Yes, but that's not going to make my Pfizer stock go up.

[–]shatabee5 2 insightful - 2 fun2 insightful - 1 fun3 insightful - 2 fun -  (0 children)

If only we had known back then...

[–]tomatopotato★ Free Assange ★ 4 insightful - 1 fun4 insightful - 0 fun5 insightful - 1 fun -  (1 child)

Rough rehash of earlier HCQ narrative:

  • Dr. Boulware publishes study claiming HCQ doesn't work.

  • TDS-afflicted media runs with it.

  • Others point out the fraud in Boulware's analysis, but the damage is already done.

  • It also comes out that Boulware didn't disclose his financial COI with Gilead (makers of deadly/expensive/competing solution remdesivir).

  • Boulware later goes on to publish a similar hit piece on Ivermectin.

And the world goes round...

[–]unagisongsBurn down Reddit! 3 insightful - 1 fun3 insightful - 0 fun4 insightful - 1 fun -  (0 children)

...and nobody will ever speak up to remove this monster from their privileged position of power.

[–]stickdog[S] 3 insightful - 1 fun3 insightful - 0 fun4 insightful - 1 fun -  (0 children)

Outcomes after Early Treatment with Hydroxychloroquine and Azithromycin: An Analysis of 30,423 COVID-19 patients

Brouqui et al reported from a French database of 30,423 COVID-19 patients of whom 535 succumbed to the illness. In great detail, the investigators report mortality according to ambulatory treatment received, hospitalization, and the course over the following six weeks.

As you can see, the most favored group was those who received the regimen of hydroxychloroquine and azithromycin early in the course of illness. Of the 30,202 patients for whom treatment information was available, 191/23,172 patients (0.82%) treated with HCQ-AZM died, compared to 344/7,030 patients (4.89%) who did not receive HCQ-AZM. All the other combinations received are reported in the figure.

Important points:

  • HCQ+AZM consistently reduced the risk of hospitalization and death
  • If hospitalized, those pre-treated with HCQ+AZM at home had a greater chance of survival

Critics say this was not a randomized trial. Patients say it does not matter, they just want to survive on HCQ + AZM! When the differences are this large, we go with what is working for patients, not a false narrative from the Bio-Pharmaceutical Complex deceiving the population on simple, safe, generic drugs.